Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Advanced Lymphoma
- Refractory Acute Myeloid Leukemia
- Refractory Leukemia
- Refractory Lymphoma
- Refractory T-Cell Lymphoma
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04470947
- Collaborators
- Roche Pharma AG
- Allcyte GmbH
- Investigators
- Not Provided
Get Well Soon